Patents by Inventor Kristian Stromgaard
Kristian Stromgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12240921Abstract: SorCS2 related lipidated cyclic peptides, cyclic peptides, lipidated linear peptides, linear peptides which may be of use in medicine, and related aspects.Type: GrantFiled: May 10, 2024Date of Patent: March 4, 2025Assignee: Teitur Trophics ApSInventors: Anders Dalby, Simon Mølgaard Jensen, Mathias Kaas Ollendorff, Kristian Strømgaard, Keld Fosgerau
-
Publication number: 20240409578Abstract: The invention regards a method for 18F-labeling of a peptide.Type: ApplicationFiled: January 26, 2022Publication date: December 12, 2024Inventors: Kristian STRØMGAARD, Matthias Manfred HERTH, Andreas KJÆR, Eduardo Felipe Alves FERNANDES, Line Bruhn Schneider KNUDSEN
-
Publication number: 20240301005Abstract: SorCS2 related lipidated cyclic peptides, cyclic peptides, lipidated linear peptides, linear peptides which may be of use in medicine, and related aspects.Type: ApplicationFiled: May 10, 2024Publication date: September 12, 2024Inventors: Anders DALBY, Simon Mølgaard JENSEN, Mathias Kaas OLLENDORFF, Kristian STRØMGAARD, Keld FOSGERAU
-
Publication number: 20230348540Abstract: The present invention relates to virally expressed peptides which bind to PDZ domains and thereby block PDZ domain mediated protein-protein interactions and expression vectors encoding these peptides. The virally expressed peptides comprise an oligomerization domain, capable of forming higher order constructs, such as trimers or tetramers, and a peptide ligand capable of binding to a PDZ domain. The invention furthermore relates to therapeutic use of said peptides and expression vectors encoding these peptides.Type: ApplicationFiled: March 5, 2021Publication date: November 2, 2023Inventors: Andreas Toft Sørensen, Kenneth Madsen, Nikolaj Christensen, Kristian Strømgaard
-
Publication number: 20230220021Abstract: The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.Type: ApplicationFiled: June 11, 2021Publication date: July 13, 2023Inventors: Javier Rodriguez Balboa, Kristian Strømgaard, Søren Østergaard
-
Publication number: 20230183335Abstract: The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1% activity of native glucagon-like peptide 1 (GLP-1) at the GLP-1 receptor, and an N-methyl-D-aspartate receptor (NMDAR) antagonist, the peptide being covalently bonded to the NMDAR antagonist either directly or through a chemical linker, the conjugated molecule for use in therapy, pharmaceutical composition comprising the conjugated molecule, a method of reducing body weight of a mammal comprising administering the conjugated molecule to the mammal, and a non-therapeutic method of reducing body weight of a mammal comprising orally administering the conjugated molecule to the mammal.Type: ApplicationFiled: June 3, 2021Publication date: June 15, 2023Inventors: Christoffer CLEMMENSEN, Anders Bue KLEIN, Jonas Odgaard PETERSEN, Bente Flensborg FRØLUND, Kristian STRØMGAARD
-
Publication number: 20220033450Abstract: The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.Type: ApplicationFiled: October 22, 2019Publication date: February 3, 2022Applicant: University of CopenhagenInventors: Andreas Toft Sørensen, Kenneth L. Madsen, Nikolaj Riis Christensen, Kristian Strømgaard
-
Publication number: 20210347821Abstract: The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.Type: ApplicationFiled: October 22, 2019Publication date: November 11, 2021Applicant: University of CopenhagenInventors: Kenneth L. Madsen, Kristian Strømgaard, Ulrik Gether, Anders Bach, Nikolaj Riis Christensen
-
Patent number: 9902754Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analog comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof, wherein an amino-terminal residue of the peptide is N-alkylated.Type: GrantFiled: December 16, 2015Date of Patent: February 27, 2018Assignee: University of CopenhagenInventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20160303245Abstract: The present invention provides fatty acid derived compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.Type: ApplicationFiled: November 26, 2014Publication date: October 20, 2016Inventors: Kristian Strømgaard, Anders Bach, Klaus Bertram Nissen
-
Publication number: 20160176924Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated.Type: ApplicationFiled: December 16, 2015Publication date: June 23, 2016Inventors: Anders Bach, Kristian Stromgaard
-
Patent number: 9241967Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated.Type: GrantFiled: July 9, 2009Date of Patent: January 26, 2016Assignee: University of CopenhagenInventors: Anders Bach, Kristian Stromgaard
-
Patent number: 9139615Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV (SEQ ID NO: 5) or YSXV (SEQ ID NO: 6), wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.Type: GrantFiled: May 11, 2012Date of Patent: September 22, 2015Assignee: University of CopenhagenInventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20140094415Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N,N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.Type: ApplicationFiled: May 11, 2012Publication date: April 3, 2014Inventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20110178022Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated.Type: ApplicationFiled: July 9, 2009Publication date: July 21, 2011Applicant: UNIVERSITY OF COPENHAGENInventors: Anders Bach, Kristian Stromgaard
-
Patent number: 7473788Abstract: The subject invention provides compounds having the structure: wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety, or an optically pure enantiomer of the compound or wherein R1 is H or OH; R2 is H, OH, halogen, unsubstituted or substituted, straight or branched (C1-C5) alkyl group, (C2-C5) alkenyl, or a (C2-C5) alkynyl, (C1-C5) alkoxy, (C2-C5) alkenyloxy, or (C2-C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6, where R5 and R6 are each independently hydrogen, substituted or unsubstituted (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl, or a cycloType: GrantFiled: December 5, 2006Date of Patent: January 6, 2009Assignee: The Trustees of Columbia University in the City of New YorkInventors: Kristian Stromgaard, Makiko Suehiro, Koji Nakanishi, Stine B. Vogensen
-
Patent number: 7429670Abstract: The subject invention provides ginkgolide C derivatives compounds having the structure: wherein R is H or -A-Ar, where A is an alkyl group; and Ar is an aryl group, which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents each selected from the group consisting of hydrogen, alkoxy, —CH2CO2R4, and —CH2CONR5R6; where R4 is an alkyl group; and R5 and R6 are each, independently, hydrogen or a branched or unbranched alkyl group; wherein R1 is H or —COR7, where R7 is alkyl, aryl or amino; wherein R2 is present or absent, and when present is H, —COR8 or —CO—Z—R8; where R8 is alkyl, aryl or amino; and Z is oxygen; wherein R3 is present or absent, and when present is —COR9; where R9 is alkyl or aryl; wherein only one of R2 or R3 is present in the compound; wherein only two of R, R1, R2 and R3 are H; and wherein each of a and b designates a single covalent bond which is present or absent, where bond a is present when R3 is absent and bond b is present when R2Type: GrantFiled: August 24, 2004Date of Patent: September 30, 2008Assignee: The Trustees of Columbia University in the City of New YorkInventors: Koji Nakanishi, Stanislav Jaracz, Kristian Stromgaard
-
Publication number: 20070098632Abstract: The subject invention provides compounds having the structure: wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety, or an optically pure enantiomer of the compound or wherein R1 is H or OH; R2 is H, OH, halogen, unsubstituted or substituted, straight or branched (C1-C5) alkyl group, (C2-C5) alkenyl, or a (C2-C5) alkynyl, (C1-C5) alkoxy, (C2-C5) alkenyloxy, or (C2-C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6, where R5 and R6 are each independently hydrogen, substituted or unsubstituted (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl, or a cyclType: ApplicationFiled: December 5, 2006Publication date: May 3, 2007Inventors: Kristian Stromgaard, Makiko Suehiro, Koji Nakanishi, Stine Vogensen
-
Patent number: 7145021Abstract: The subject invention provides compounds having the structure: wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent-moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety, or an optically pure enantiomer of the compound or wherein R1 is H or OH; R2 is H, OH, halogen, unsubstituted or substituted, straight or branched (C1–C5) alkyl group, (C2–C5) alkenyl, or a (C2–C5) alkynyl, (C1–C5) alkoxy, (C2–C5) alkenyloxy, or (C2–C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6, where R5 and R6 are each independently hydrogen, substituted or unsubstituted (C1–C5) alkyl, (C2–C5) alkenyl, or (C2–C5) alkynyl, or a cycloType: GrantFiled: March 28, 2003Date of Patent: December 5, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Kristian Stromgaard, Makiko Suehiro, Koji Nakanishi, Stine B. Vogensen
-
Publication number: 20050119336Abstract: The subject invention provides ginkgolide C derivatives compounds having the structure: wherein R is H or -A-Ar, where A is an alkyl group; and Ar is an aryl group, which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents each selected from the group consisting of hydrogen, alkoxy, —CH2CO2R4, and —CH2CONR5R6; where R4 is an alkyl group; and R5 and R6 are each, independently, hydrogen or a branched or unbranched alkyl group; wherein R1 is H or —COR7, where R7 is alkyl, aryl or amino; wherein R2 is present or absent, and when present is H, —COR8 or —CO-Z-R8; where R8 is alkyl, aryl or amino; and Z is oxygen; wherein R3 is present or absent, and when present is —COR9; where R9 is alkyl or aryl; wherein only one of R2 or R3 is present in the compound; wherein only two of R, R1, R2 and R3 are H; and wherein each of a and b designates a single covalent bond which is present or absent, where bond a is present when R3 is absent and bond b is preseType: ApplicationFiled: August 24, 2004Publication date: June 2, 2005Inventors: Koji Nakanishi, Stanislav Jaracz, Kristian Stromgaard